Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.

@article{Lee2005MetabolicMW,
  title={Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.},
  author={Leong Hwee Lee and Ross Campbell and Michaela Scheuermann-Freestone and Rachel Williamson Taylor and Prasad Gunaruwan and Lynne Williams and Houman Ashrafian and John David Horowitz and Alan G Fraser and Kieran Clarke and Michael P. Frenneaux},
  journal={Circulation},
  year={2005},
  volume={112 21},
  pages={3280-8}
}
BACKGROUND Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We assessed the effects of perhexiline treatment in CHF patients. METHODS AND RESULTS In a double-blind fashion, we randomly assigned patients with optimally medicated CHF to either perhexiline (n=28) or… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 139 extracted citations

Concomitant diabetes mellitus and heart failure.

Current problems in cardiology • 2015
View 19 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Feasibility and reproducibility of off-line tissue Doppler measurement of regional myocardial function during dobutamine stress echocardiography.

European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology • 2003

Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy

G Fragasso, PM Piatti, +6 authors A. Margonato
Am Heart J. 2003;146:E18. Abstract • 2003

Similar Papers

Loading similar papers…